1	Emergence and transmission dynamics of the FY.4 Omicron variant in Kenya
2 3	Authors:
4	Sebastian Musundi ¹ , Mike J. Mwanga ¹ , Arnold W. Lambisia ¹ , John Mwita Morobe ¹ , Nickson
5	Murunga ¹ , Edidah Moraa ¹ , Leonard Ndwiga, Robinson Cheruyoit ¹ , Jennifer Musyoki ¹ , Martin
6	Mutunga ¹ , Laura M Guzman-Rincon ^{1,2} , Charles Sande ¹ , Joseph Mwangangi ¹ , Philip Bejon ¹ ,
7	Lynette Isabella Ochola-Oyier ¹ , D James Nokes ^{1,2} , Charles N. Agoti ¹ , Joyce Nyiro ¹ , George
8	Githinji ^{1#}
9	
10	
11	Affiliations:
12	¹ KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
13	² University of Warwick, Coventry, UK.
14	
15	
16	*Corresponding author: ggithinji@kemri-wellcome.org
17	
18	
19	Target journal: Virus evolution
20	
21	
22	Keywords: FY.4, Omicron, Kenya, Phylogenetics

23 Abstract (words=175)

The recombinant FY.4 SARS-CoV-2 variant was first reported in Kenya in March 2023 and was 24 25 the dominant circulating variant between April and July 2023. The variant was characterised by two important mutations: Y451H in the receptor binding domain of the spike protein and P42L in 26 27 open reading frame 3a. Using phylogenetics and phylodynamic approaches, we investigated the emergence and spread of the FY.4 in Kenya and the rest of the world. Our findings suggest FY.4 28 29 circulated early in Kenya before export to North America and Europe. Early circulation of FY.4 in Kenya was predominantly observed in the coastal part of the country and the estimated time to 30 the most recent common ancestor suggests FY.4 circulated as early as December 2022. The 31 collected genomic and epidemiological data show that the FY.4 variant led to a large local outbreak 32 33 in Kenya and resulted in localised outbreaks in Europe, North America and Asia-pacific. These findings underscore the importance of sustained genomic surveillance especially in under sampled 34 35 regions in deepening our understanding of the evolution and spread of SARS-CoV-2 variants.

37 Introduction

38 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan China in late 2019 (Lu et al., 2020; Zhu et al., 2020). Over the past five years, SARS-CoV-2 has evolved into 39 40 several lineages, some of which are more transmissible than others and reduce effectiveness to public health interventions such as therapeutics, diagnostics and vaccines (Centre for Disease 41 42 Control and Prevention, 2021). The World Health Organization (WHO) designated these lineages as variant of concern (VOC) (https://www.who.int/activities/tracking-SARS-CoV-2-variants). 43 44 The VOCs include Alpha (B.1.17) (Hill et al., 2022), Beta (B.1.35) (Tegally et al., 2021), Gamma (P.1) (Faria et al., 2021), Delta (B.1.617.2) (Cherian et al., 2021) and Omicron(Viana et al., 2022). 45 46 The Omicron variant was first reported on 24th November 2021 in South Africa and Botswana 47 and carried over 30 mutations in the spike protein compared to the Wuhan-Hu-1 strain (Tegally et 48 al., 2022; Viana et al., 2022). The presence of these mutations increased transmissibility and reduced neutralization by anti-SARS-CoV-2 antibodies (Planas et al., 2022). While the origin of 49 50 the Omicron remains debatable, possible hypotheses explaining its emergence include extreme 51 under-sampling resulting in undetected lineages, zoonotic spillover from animals that transmit 52 SARS-CoV-2 without an intermediate host like the white-tailed deer and farmed mink and 53 persistence of the virus in chronically infected individuals (Markov et al., 2023).

54

The Omicron variant was initially classified into three lineages BA.1, BA.2 and BA.3 before the 55 emergence of BA.4 and BA.5 (Tegally et al., 2022). Unlike previous waves of VOCs which were 56 57 driven by few circulating variants (Li et al., 2021), the emergence of Omicron led to convergent 58 evolution and diversification (Andreis et al., 2023; Ito et al., 2023), resulting in multiple co-59 circulating lineages and an increased probability of recombination events. In mid-August 2022, the XBB recombinant was reported in India, Singapore and other parts of Asia (Wang et al., 2023). 60 XBB emerged from two BA.2 omicron variants BM.1.1.1 (BA.2.75.3.1.1.1) and BJ.1 61 (BA.2.10.1.1) with breakpoints located in the receptor-binding domain of spike protein (Tamura 62 63 et al., 2023). XBB showed increased immune resistance, fusogenicity and binding affinity to angiotensin-converting enzyme 2(ACE2), the receptor mediating viral infection compared to the 64 65 parental strains (Tamura et al., 2023). Since then, multiple XBB variants such as XBB.1.5 (Parums, 66 2023), and XBB.1.16 (Looi, 2023) emerged and spread across the globe.

68 The FY.4 (XBB.1.22.1.4) omicron variant became the dominant lineage in Kenya between March to July 2023 in Kenya following its initial detection on 10th March 2023 (Mwanga et al., 2023). 69 70 Globally, the first FY.4 sample outside Kenya was reported first on 3rd April 2023 in Germany (Khare et al., 2021). In this work, we aimed to understand the origin and transmission of the FY.4 71 72 Omicron sub-variant using genomic data. FY.4 circulated as early as December 2022 and was 73 observed in Kenya first before being exported to other regions of the world. These findings suggest 74 FY.4 potentially originated from Kenya and underscores the importance of genomic surveillance in tracking SARS-CoV-2 variants. 75

- 76
- 77

78 Methods

79 Data sources

80 SARS-CoV-2 FY.4 samples (n=73) used for analysis in this study were generated at Kenya Medical Research Institute Wellcome Trust Research Programme (KWTRP) as previously 81 82 described (Mwanga et al., 2023). An additional (n=139) FY.4 genomes sequenced within Kenya 83 and across the globe were retrieved from Global Initiative for Sharing all Influenza Data (GISAID). Consensus 84 genomes for FY.4 lineages and XBB were retrieved from 85 (https://github.com/corneliusroemer/pango-sequences) and aligned using MAFFT. Amino acid 86 mutations relative to the Wuhan-HU-1 and XBB and were plotted using SNIPit (O'Toole et al., 87 2024).

88

89 Time-scaled analysis of the FY.4 variant

90 We compiled a dataset of circulating SARS-CoV-2 sequences in Kenya between October 2022 and October 2023 (n=1,078). Out of these 73 genomes were sequenced at KWTRP and an 91 92 additional (n=139) sequenced locally in Kenya, making a total of 212 Kenyan FY.4 sequences. 93 We analysed this dataset against a background of FY.4 global sequences retrieved from GISAID 94 (n=755). The global dataset from where the sequences were obtained are summarized in Supplementary Table 1. Sequences with less than 70% genome coverage (n=1), incomplete 95 collection dates (n=11), and whose lineage were misclassified based on NextClade version 3.8.2 96 97 (n=5) were excluded from further analysis. The remaining sequences were aligned against the SARS-CoV-2 (XBB) reference (a Wuhan-Hu-1/2019 reference (Accession number MN908947.3) 98

99 containing XBB single nucleotide polymorphisms) using MAFFT version 6.240 (Katoh & 100 Standley, 2013). The alignment was visualized using AliView version 1.28 (Larsson, 2014) and 101 the 5' and 3' ends containing the untranslated regions were manually trimmed. A maximum 102 likelihood (ML) tree was generated using IQ-TREE version 2.3.3 with 1000 bootstrap values using 103 the General Time Reversible (GTR) model (Nguyen et al., 2015). The maximum likelihood tree 104 was visualized using the R package "ggtree" and low-quality sequences (n=16) dropped from the 105 tree using the R package "ape." A time-resolved maximum likelihood tree was then generated using Treetime (Sagulenko et al., 2018). 106

107

108 Phylogeography analysis

109 The presence of a molecular signal was evaluated using TempEst version 1.5.3 (Rambaut et al., 110 2016) prior to Bayesian analysis using BEAST (Drummond & Rambaut, 2007). To identify the 111 clades circulating within Kenya, a discrete phylogeography approach utilizing two locations; 112 "Kenya" and "Others" was run in BEAST 1.10.4. This approach utilized the time-resolved 113 phylogeny as the starting tree to reduce computational time needed to generate transmission 114 information(Bollen et al., 2021). Bayesian inference was run using BEAST v1.10.4 for 6 x 10^5 115 Monte Carlo Markov Chain (MCMC) and sampling every 1000 step. Log files were checked for 116 convergence and mixing using Tracer v1.7.1 (Rambaut et al., 2018). After discarding 10% as burn-117 in, a maximum clade credibility tree (MCC) generated using TreeAnnotator version 1.10.4 118 (Suchard et al., 2018). The overall number of transitions between the two locations was counted 119 in BEAST package Babel utilizing sampled trees.

120

121 To explore the local transmission of the FY.4 variant within Kenya, the relaxed random walk 122 (RRW) diffusion model which allows for dispersal velocity in the tree to vary but remain the same 123 in the branches was inferred using the longitude and latitudes of sample locations as continuous 124 traits (Lemey et al., 2010; Pybus et al., 2012). Since the RRW model does not allow samples to 125 have the same geographical coordinates, we selected the centroid location of each administrative 126 point and added random jitter of 0.05 to each tip making each location distinct. A MCMC chain 127 was run in duplicate for 500 million iterations sampled after every 50,000 steps with its mixing properties checked in Tracer v.1.71 to ensure the effective sample size (ESS) is >200. The R 128 129 package "seraphim" used to extract spatiotemporal information embedded in the posterior,

maximum clade credibility trees and visualize the dispersal of FY.4 within Kenyan counties(Dellicour et al., 2016).

132

133 Next, we carried out a discrete phylogeographic analysis to infer the global origin and movement 134 of FY.4 across different regions across the globe. We aggregated the country of sampling into four 135 regions including Kenya (n=206), North America (n=494), Europe (n=140) and Asia-Pacific (Asia 136 and Oceania) (n=91). One sample from South America and two samples from Uganda were 137 excluded to minimize biased posterior distributions due to unequal sample size. In addition, we analyzed samples collected from March 2023 considering the first case was reported on 10th March 138 139 2023. By focusing on this timeline, we aimed to capture the spread of FY.4 from the time it was 140 initially identified providing a clear evolutionary trajectory of the geographic spread of FY.4 while 141 in circulation. During this study, three additional FY.4 sequences were recently deposited in GISAID from Nakuru, Kenya with collection dates ranging between 11th -14th November 2022. 142 Although these sequences predate the first reported case suggesting earlier circulation, we 143 144 excluded these samples due to insufficient information from very few samples collected in 145 November 2022 and absence of samples collected between November 2022 and March 2023. 146 Since a large number of sequences originated from the USA, down sampling was carried out based 147 on time, pangolin lineage and region resulting in a total of 511 sequences distributed as follows: 148 Kenya (n=94), North America (n=233), Europe (n=107) and Asia-Pacific (n=77). Ancestral 149 locations reconstruction of the FY.4 variant and asymmetric viral exchanges between regions was 150 estimated utilizing a non-continuous time Markov chain model. The Bayesian stochastic search 151 variable selection was used to infer non-zero migration rates and identify the best-supported 152 transitions rates using a bayes factor test. In addition, Markov jump counting was used to estimate 153 the number of transitions across the different regions. The time-scaled phylogeny was created 154 using the HKY substitution model with a gamma distributed rate for invariant sites, an uncorrelated 155 relaxed molecular clock with a log normal prior and Bayesian skygrid with 52 change points over 156 a period of one year. The analysis was run in duplicate on BEAST v1.10.4 using 200 million 157 MCMC steps with sampling after every 20000 steps. Mixing and convergence properties were 158 assessed using Tracer v.1.71 ensuring the ESS was >200. After discarding the 10% burn-in, the 159 MCC tree was constructed using TreeAnnotator version 1.10 and the number of 160 transitions/Markov jumps estimated using TreeMarkovJumpHistoryAnalyzer (Lemey et al., 2021).

161

162 Results

163

FY.4 circulated in Kenya before global expansion and underwent rapid evolution over a short period of time.

166 FY.4 variant became the dominant circulating lineage in Kenyan between March and July 2023 167 before eventual replacement with other Omicron subvariants (Figure 1A). The period coincides 168 with the high positivity rate observed from samples collected from health facilities within the Kilifi 169 Health Demographic Surveillance System (KHDSS) (Supplementary Figure 1). On the global 170 scale, FY.4 was first detected in Africa before its eventual detection in other continents across the 171 globe (Figure 1B). In Africa, FY.4 circulation peaked between April and May 2023 while in North 172 America and Europe the peak was observed in July 2023 (Figure 1B). In Africa, sublineage FY.4.1 173 was the dominant circulating lineage and co-circulated with its expanded lineage FY.4.1.2. North 174 America initially saw FY.4.1 and FY.4.2 in April 2023 followed by FY.4.1.2 before the co-175 circulation of FY.4.2 and FY.4.1.1 in the later stages. FY.4.1 and FY.4.1.2 were the main 176 circulating lineages in Europe from April 2023 and while the same lineages were initially detected 177 in Asia from May 2023, FY.4.2 became the main circulating lineage thereafter from June to 178 September 2023 (Figure1B).

179

180 Phylogenetic analysis of the circulating strains in Kenya (n=1078) between October 2022 and 181 October 2023, showed that FY.4 was closely related to other XBB variants and more specifically 182 XBB.1.16 and XBB.1.9 (Supplementary Figure 2). As expected, FY.4 was also present in the same 183 clade as BA.2 and BA.2.75 which has previously been proposed as the main parental lineages for 184 the emergence of the recombinant XBB. In addition to the two lineage-defining mutations-Y451H 185 in the spike protein and P42L in ORF3a- expanded sub-lineages exhibited notable mutations. 186 FY.4.1 contained S494P in the receptor binding domain of spike glycoprotein while FY.4.1.1 187 included S704L in subdomain 2. The FY.4.1.2 sub-lineage was characterized by S2926F in ORF1a 188 and FY.4.2 displayed mutations Y2171F in ORF1a and V2287I in ORF1b.

189

190 A time-resolved tree ML tree containing Kenyan (n=207) FY.4 and global sequences (n=738)

revealed a short period between the expansion of FY.4.1 to FY.4.1.1 and FY.4.1.2 suggesting a

192 rapid diversification process (Figure 1C). Following its expansion, FY.4.1 persisted for 36 weeks

193 in circulation together with its derived lineages. In contrast, FY.4.2, which also emerged from FY.4, did not expand to additional lineages, likely reflecting the different selective pressures acting 194 195 on individual FY.4 lineages. Analysis of the temporal spread revealed FY4 circulated early in Kenya compared to other regions of the globe (Figure 1C). Additionally, Kenyan FY.4 sequences 196 197 displayed significant genetic diversity by mapping to multiple lineages and formed clusters providing evidence for local transmission ahead of introductions to other regions (Figure 1C). 198



- 200
- 201 202

203 Figure 1. Circulation of the FY.4 omicron subvariant. A) Proportion of SARS-CoV-2 lineages 204 circulating in Kenya from September 2022 to January 2024. FY.4 circulated in Kenya 205 predominantly from March to September 2023. B) Global distribution of circulating FY.4 variants 206 from November 2022 to January 2024. The individual colours represent the FY.4 sub-lineages while the size of the circle denotes the number of genomes deposited in GISAID per month. C) 207 Time-resolved phylogenetic tree showing the temporal clustering of FY.4 between Kenya and 208 global sequences. The colours represent the location the sample was collected from, and the shape 209 210 represent the FY.4 pangolin sub-lineages.

212 The FY.4 variant originated in Kenya.

213 The presence of a temporal signal was confirmed by the linear relationship between genetic 214 divergence and sampling dates using TempEst version 1.5.3 (R²=0.326) (Figure 2A). Subsequently, we carried out a discrete phylogeographic analysis to identify the potential origin 215 216 and the number of import and export events to Kenya using the FY.4 variant using genomic data. 217 Based on this, we observed no evidence of independent introductions of FY.4 in Kenya (Figure 218 2B) based on the 95% highest posterior density (HPD) ([0-1]) However, we identified at least 75 219 transmission events from Kenya to the rest of the globe (95% HPD interval = [73-79]). Local 220 transmission dynamics in Kenya, comprised of over 485 transition events between counties (95% HPD interval= [480-489]) (Figure 2B). Evidence of spread is supported by export and imports 221 222 events between the counties. Global spread was observed with support for multiple export events 223 (1,304 transition events (95% HPD interval = [1298-1312]) across the globe showing FY.4 arrived 224 and transmitted across multiple regions.

225

226 Ancestral reconstruction analysis revealed the presence of two most common recent ancestors. The 227 first node infers Kenyan ancestry and included all Kenyan sequences alongside global sequences 228 forming the largest clade with 915 sequences (Figure 2C). The genetic diversity of the Kenyan sequences in this node supports strong local transmission within Kenya while the presence of both 229 230 Kenyan and global sequences in the same node suggests possible worldwide dissemination of the 231 FY.4 variant. In contrast, the second ancestral node was associated with fewer sequences (n=19) 232 and likely represented a more localized transmission route. Notably, the second ancestral node did 233 not include Kenyan samples which might suggest limited or no transmission to or from Kenya or 234 a pathway that completely bypassed Kenya (Figure 2C).





236

237 Figure 2. Preliminary phylogeography discrete trait analysis. A) Root-to-tip regression from TempEst analysis showing the presence of a temporal signal ($R^2 = 0.326$, correlation coefficient = 238 0.57). The FY.4 sequences are colored according to the locations (Kenya or Global). The 239 240 regression line represents the estimate mean evolutionary rate with error buffers in grey showing the 90% confidence intervals. B). The number of transitions was derived from the MCC tree by 241 counting changes between "Kenyan" and "Other" locations. Transitions were counted when the 242 location of the internal node changed from "Kenya" to "Others" or vice versa or when maintained 243 in the same position. C) Preliminary discrete trait analysis identified two ancestral clades 244 associated with spread of FY.4 using a fixed time-resolved tree. The green tips represent individual 245 246 Kenya samples, black the most probable location for Kenyan sequences and background grey the most probable location for global sequences. Two ancestral nodes are filled by the plum and 247 salmon colours respectively. The "Other" ancestral node occurs primarily on the FY.4.2 sub-248 249 lineage which was not largely observed in Kenya but was predominant in North America.

250

We extracted the ancestral clade that inferred Kenyan ancestry and examined virus dispersal within Kenya. The subsequent continuous phylogeography of patterns of dispersal within Kenya supported the evidence that FY.4 was the dominant circulating lineage in coastal region from

254 March 2023. By May-June 2023, most cases were observed centrally in the capital city (Figure 3).

Most peripheral samples also directly connected to either the coastal region or centrally in the capital city which were the predominant sampling sites. This pattern likely suggests a limited geographical range of sampling in Kenya, potentially leading to an underestimate of the circulation of FY.4 in other parts of Kenya.



259

Figure 3. Dispersal of FY.4 across Kenya over time based on 1000 subsampled trees from a
 continuous phylogeographic posterior distribution. The nodes of the MCC tree are color-coded
 based on the time of occurrence. The 80% HPD regions are displayed in successive layers with
 the colors reflecting corresponding time periods for virus spread.

264

265 Phylogeographic reconstruction implied that FY.4 may have emerged in Kenya in early January

266 (mean tMRCA 3rd January, 95% HPD 2nd December 2022- 1st February 2023) (Figure 4A).

267 Thereafter, FY.4 was first exported to Europe then to North America in week 7 and 9 respectively

and later exported to Asia-Pacific around week 13 (Figure 4B). Out of the 60 export events from Kenya, most were to North America (n=32), followed by Europe (n=19) and lastly Asia-Pacific (n=9) (Figure 4B). There were no inferred introductions from the globe into to Kenya during this period. An exponential increase in the effective population size was observed between January and April 2023 followed by a minor decline and another slight exponential increase from August to September before a decline to January 2024 (Figure 4C).

274



275 276

Figure 4. Bayesian phylogeographic reconstruction of FY.4. A) Time-resolved maximum
credibility clade tree with branches coloured by inferred geographic location. B) A summary of
the number of Markov Jumps from Kenya to other regions stratified by epidemiological weeks. C)
A Bayesian Skyline plot describing the inferred change in the effective population size of FY.4
infections over time.

282 283

284 Discussion

The FY.4 variant increased in circulation in Kenya between March and July 2023 accounting for increased cases and hospitalization (Mwanga et al., 2023). This variant was also observed in other regions across the globe (Figure 1C). Given the early isolation of FY.4 and increased transmission intensity in Kenya, we applied genomic and epidemiological data to investigate the emergence and

transmission dynamics of FY.4 variant from sequenced samples in Kenya in addition to thosecollected from the globe.

291

292 The FY.4 lineage of SARS-COV-2 is characterized by two notable mutations namely the Y451H 293 in the receptor binding domain (RBD) of the spike protein, whose functional implication is unclear and the P42L in the ORF3a, with potential for contribution to the loss of recognition of T-cell 294 295 epitope (de Silva et al., 2021). Additionally, the S494P present in the RBD of FY.4.1 enhances binding affinity to ACE2 receptor increasing transmissibility (Chakraborty, 2021) and potentially 296 297 contributing to the increased number of observed cases. Neutralization assays against multiple 298 circulating Omicron variants including FY.4 in Kenya between March 2023-March 2024 have 299 provided evidence for decline in naturally acquired and vaccine-mediated antibody responses 300 implying that the Kenyan population was still susceptible to infections caused by emerging 301 Omicron subvariants. (Lugano et al., unpub. data doi.org/10.1101/2024.06.26.24309525). Here, 302 we used an established health facilities surveillance platform (Nyiro et al., 2018), and combined 303 this with further local and global genomic data to determine the origin and describe the 304 transmission dynamics of this variant.

305

306 The phylogenetic and phylogeographic reconstruction suggests that Kenya was the potential origin 307 of the FY.4 variant (Figure 2B). Phylogenetic and phylogenomic analysis provides evidence for 308 multiple exportation events from Kenya, primarily to North America and Europe (Figure 3B) 309 which occurred between March and July 2023. Previously we have observed multiple 310 introductions of ancestral strains (Githinji et al., 2021) and variants of concern (Agoti et al., 2022; 311 Githinji et al., unpub. data doi.org/10.1101/2022.10.26.22281446). The Bayesian skyline plot 312 showed that the effective population size corresponded with increase in the number of cases and 313 potentially indicate missed cases during the outbreak period. A peak in the effective population 314 size was observe between August and September 2023 suggesting a surge in cases outside of 315 Kenya and this coincides with a rise in the FY.4 genome sequences deposited from North America 316 and Europe (Figure 3C). This suggests ongoing transmission events between Kenya and the rest 317 of the world following the initial emergence of FY.4.

A limitation with this study is that the true number of FY.4 derived COVID-19 cases in Kenya,

320 African and South America is likely underestimated given the limited number of tests at the period,

321 under-surveillance and the limited genomic surveillance in the country. The biased sampling is

- 322 underscored by clustered outbreaks in areas with higher sampling rates.
- 323

324 Conclusion

Genomic surveillance is essential in identifying emerging variants of SARS-CoV-2. In this study, the use of phylogenetics and phylodynamic approaches provided insights to the possible origin and dispersal patterns of the FY.4 variant The study reinforces the need for increased sequencing capacity especially in under-sampled geographic regions especially in studying the evolution of SARS-CoV-2.

330

331332 Data Availability

The raw data files and consensus genome sequences obtained in this study were submitted to both GISAID and GenBank databases and the accession numbers prepared for deposition in Harvard DataVerse (https://doi.org/10.7910/DVN/VPWUXN). For more detailed information beyond the metadata used in the paper, there is a process of managed access requiring submission of a request form for consideration by our Data Governance Committee.

338

339 Acknowledgments

340 We thank the members of our field study team involved in collecting the samples, the members of the KWTRP COVID-19 testing team, PEO research group members that undertook real-time RT-341 342 PCR processing. This work was support by multiple funding sources that included the New Variant 343 Assessment Platform (NVAP), Wellcome grants (220985/Z/20/Z and 226002/A/22/Z). The 344 Rockerfeller Foundation subaward (OXFFDG01) and the Department of Health and Social Care 345 grant (project references 17/63/82 and 16/136/33). The views expressed in this publication are 346 those of the author (s) and not necessarily those of the Department of Health and Social Care, 347 Foreign Commonwealth and Development Office, Wellcome Trust or the UK government. 348

349 This manuscript was published with permission from the Director General

350

Role of funders

The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.

354

355 Author's contributions

- 356 The project was conceived and designed by GG; Project supervision and funding was obtained by
- 357 GG, CNA, LI, JN, DJN; Laboratory processing of the samples was conducted by MM, AWL, JM,
- EM, LK, RC, JM, MM, LG; Data management and analysis was carried out by NM,SM,LN.
- 359 SM,GG wrote the initial draft and GG, CNA, PB, reviewed the manuscript and produced the final
- 360 draft. All authors contributed to and reviewed the final draft.

361 References

362 363 364 365 366 367	 Agoti, C. N., Ochola-Oyier, L. I., Dellicour, S., Mohammed, K. S., Lambisia, A. W., de Laurent, Z. R., Morobe, J. M., Mburu, M. W., Omuoyo, D. O., Ongera, E. M., Ndwiga, L., Maitha, E., Kitole, B., Suleiman, T., Mwakinangu, M., Nyambu, J. K., Otieno, J., Salim, B., Musyoki, J., Githinji, G. (2022). Transmission networks of SARS-CoV-2 in Coastal Kenya during the first two waves: A retrospective genomic study. <i>ELife</i>, <i>11</i>. https://doi.org/10.7554/eLife.71703
368 369 370 371 372	 Andreis, T. F., Cantarelli, V. V., da Silva, M. B., Helfer, M. S., Brust, F. R., Zavascki, A. P., Westercamp, M., Tashayev, V., Donadel, M., Magleby, R., Petersen, E., & Mahon, G. (2023). Substantial Diversity in Cocirculating Omicron Lineages in Hospital Setting, Porto Alegre, Brazil. <i>Emerging Infectious Diseases</i>, 29(12). https://doi.org/10.3201/eid2912.230880
373 374 375 376 377 378	 Bollen, N., Artesi, M., Durkin, K., Hong, S. L., Potter, B., Boujemla, B., Vanmechelen, B., Martí-Carreras, J., Wawina-Bokalanga, T., Meex, C., Bontems, S., Hayette, M. P., André, E., Maes, P., Bours, V., Baele, G., & Dellicour, S. (2021). Exploiting genomic surveillance to map the spatio-temporal dispersal of SARS-CoV-2 spike mutations in Belgium across 2020. <i>Scientific Reports</i>, <i>11</i>(1). https://doi.org/10.1038/s41598-021-97667-9
379 380	Center for Disease Control and Prevention. (2021). SARS-CoV-2 Variant Classifications and Definitions. https://stacks.cdc.gov/view/cdc/105817
381 382 383 384	 Chakraborty, S. (2021). Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity. <i>Biochemical and Biophysical Research Communications</i>, <i>534</i>. https://doi.org/10.1016/j.bbrc.2020.11.075
385 386 387 388	Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Rakshit, P., Singh, S., Abraham, P., & Panda, S. (2021). Sars-cov-2 spike mutations, 1452r, t478k, e484q and p681r, in the second wave of covid-19 in Maharashtra, India. <i>Microorganisms</i> , 9(7). https://doi.org/10.3390/microorganisms9071542
389 390 391 392 393	 de Silva, T. I., Liu, G., Lindsey, B. B., Dong, D., Moore, S. C., Hsu, N. S., Shah, D., Wellington, D., Mentzer, A. J., Angyal, A., Brown, R., Parker, M. D., Ying, Z., Yao, X., Turtle, L., Dunachie, S., Aanensen, D. M., Abudahab, K., Adams, H., Dong, T. (2021). The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. <i>IScience</i>, 24(11). https://doi.org/10.1016/j.isci.2021.103353
394 395 396	Dellicour, S., Rose, R., Faria, N. R., Lemey, P., & Pybus, O. G. (2016). SERAPHIM: Studying environmental rasters and phylogenetically informed movements. <i>Bioinformatics</i> , 32(20). https://doi.org/10.1093/bioinformatics/btw384

397	Drummond, A. J., & Rambaut, A. (2007). BEAST: Bayesian evolutionary analysis by
398	sampling trees. <i>BMC Evolutionary Biology</i> , 7(1). https://doi.org/10.1186/1471-2148-7-
399	214
400	 Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S.,
401	Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., Hulswit, R. J. G.,
402	Franco, L. A. M., Ramundo, M. S., De Jesus, J. G., Andrade, P. S., Coletti, T. M.,
403	Ferreira, G. M., Silva, C. A. M., Manuli, E. R., Sabino, E. C. (2021). Genomics and
404	epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. <i>Science</i> , <i>372</i> (6544).
405	https://doi.org/10.1126/science.abh2644
406	 Githinji, G., de Laurent, Z. R., Mohammed, K. S., Omuoyo, D. O., Macharia, P. M.,
407	Morobe, J. M., Otieno, E., Kinyanjui, S. M., Agweyu, A., Maitha, E., Kitole, B.,
408	Suleiman, T., Mwakinangu, M., Nyambu, J., Otieno, J., Salim, B., Kasera, K., Kiiru, J.,
409	Aman, R., Agoti, C. N. (2021). Tracking the introduction and spread of SARS-
410	CoV-2 in coastal Kenya. <i>Nature Communications</i> , <i>12</i> (1).
411	https://doi.org/10.1038/s41467-021-25137-x
412 413 414 415 416	 Githinji, G., Lambisia, A., Omah, I., medRxiv, A. O, & 2022, undefined. (n.d.). The genomic epidemiology of SARS-CoV-2 variants of concern in Kenya. <i>Medrxiv.OrgG Githinji, AW Lambisia, I Omah, A O'Toole, KS Mohamed, ZR de Laurent, TO MakorimedRxiv, 2022-medrxiv.Org.</i> Retrieved October 15, 2024, from https://www.medrxiv.org/content/10.1101/2022.10.26.22281446.abstract
417 418 419 420 421	 Hill, V., Plessis, L. Du, Peacock, T. P., Aggarwal, D., Colquhoun, R., Carabelli, A. M., Ellaby, N., Gallagher, E., Groves, N., Jackson, B., McCrone, J. T., O'Toole, Á., Price, A., Sanderson, T., Scher, E., Southgate, J., Volz, E., Barclay, W. S., Barrett, J. C., Rambaut, A. (2022). The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. <i>Virus Evolution</i>, 8(2). https://doi.org/10.1093/ve/veac080
422	Ito, J., Suzuki, R., Uriu, K., Itakura, Y., Zahradnik, J., Kimura, K. T., Deguchi, S., Wang,
423	L., Lytras, S., Tamura, T., Kida, I., Nasser, H., Shofa, M., Begum, M. M., Tsuda, M.,
424	Oda, Y., Suzuki, T., Sasaki, J., Sasaki-Tabata, K., Sato, K. (2023). Convergent
425	evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1
426	variant. <i>Nature Communications</i> , 14(1). https://doi.org/10.1038/s41467-023-38188-z
427 428 429	Katoh, K., & Standley, D. M. (2013). MAFFT multiple sequence alignment software version 7: Improvements in performance and usability. <i>Molecular Biology and Evolution</i> , 30(4). https://doi.org/10.1093/molbev/mst010
430 431 432 433	 Khare, S., Gurry, C., Freitas, L., Schultz, M. B., Bach, G., Diallo, A., Akite, N., Ho, J., Lee, R. T. C., Yeo, W., Team, G. C. C., & Maurer-Stroh, S. (2021). GISAID's Role in Pandemic Response. <i>China CDC Weekly</i>, <i>3</i>(49). https://doi.org/10.46234/ccdcw2021.255

434	Larsson, A. (2014). AliView: A fast and lightweight alignment viewer and editor for large
435	datasets. <i>Bioinformatics</i> , 30(22). https://doi.org/10.1093/bioinformatics/btu531
436	Lemey, P., Rambaut, A., Welch, J. J., & Suchard, M. A. (2010). Phylogeography takes a
437	relaxed random walk in continuous space and time. <i>Molecular Biology and Evolution</i> ,
438	27(8). https://doi.org/10.1093/molbev/msq067
439	Lemey, P., Ruktanonchai, N., Hong, S. L., Colizza, V., Poletto, C., Van den Broeck, F.,
440	Gill, M. S., Ji, X., Levasseur, A., Oude Munnink, B. B., Koopmans, M., Sadilek, A.,
441	Lai, S., Tatem, A. J., Baele, G., Suchard, M. A., & Dellicour, S. (2021). Untangling
442	introductions and persistence in COVID-19 resurgence in Europe. <i>Nature</i> , 595(7869).
443	https://doi.org/10.1038/s41586-021-03754-2
444 445 446	Li, J., Lai, S., Gao, G. F., & Shi, W. (2021). The emergence, genomic diversity and global spread of SARS-CoV-2. In <i>Nature</i> (Vol. 600, Issue 7889). https://doi.org/10.1038/s41586-021-04188-6
447 448	Looi, M. K. (2023). What do we know about the Arcturus XBB.1.16 subvariant? <i>BMJ</i> (<i>Clinical Research Ed.</i>), 381. https://doi.org/10.1136/bmj.p1074
449 450 451 452	Lu, J., du Plessis, L., Liu, Z., Hill, V., Kang, M., Lin, H., Sun, J., François, S., Kraemer, M. U. G., Faria, N. R., McCrone, J. T., Peng, J., Xiong, Q., Yuan, R., Zeng, L., Zhou, P., Liang, C., Yi, L., Liu, J., Ke, C. (2020). Genomic Epidemiology of SARS-CoV-2 in Guangdong Province, China. <i>Cell</i> , 181(5). https://doi.org/10.1016/j.cell.2020.04.023
453 454 455 456 457 458	 Lugano, D., Kutima, B., Kimani, M., Sigilai, A., Gitonga, J., Karani, A., Akech, D., Karia, B., Ziraba, A. K., Maina, A., Omuoyo, D., Mugo, D., Lucinde, R., Newman, J., Nduati, E., Githinji, G., Agoti, C. N., Bejon, P., Anthony, J. G., Nyagwange, J. (2023). Evaluation of population immunity against SARS-CoV-2 variants, EG. 5.1, FY. 4, BA. 2.86, JN. 1, and JN. 1.4, using samples from two health demographic surveillance. <i>Medrxiv.OrgDI</i> https://doi.org/10.1101/2024.06.26.24309525
459	Markov, P. V., Ghafari, M., Beer, M., Lythgoe, K., Simmonds, P., Stilianakis, N. I., &
460	Katzourakis, A. (2023). The evolution of SARS-CoV-2. In <i>Nature Reviews</i>
461	<i>Microbiology</i> (Vol. 21, Issue 6). https://doi.org/10.1038/s41579-023-00878-2
462	 Mwanga, M. J., Lambisia, A. W., Morobe, J. M., Murunga, N., Moraa, E., Ndwiga, L.,
463	Cheruiyot, R., Musyoki, J., Mutunga, M., Guzman-Rincon, L. M., Sande, C.,
464	Mwangangi, J., Bejon, P., Ochola-Oyier, L. I., Nokes, D. J., Agoti, C. N., Nyiro, J., &
465	Githinji, G. (2023). New SARS-CoV-2 Omicron Variant with Spike Protein Mutation
466	Y451H, Kilifi, Kenya, March-May 2023. <i>Emerging Infectious Diseases</i> , <i>29</i> (11).
467	https://doi.org/10.3201/eid2911.230894

468	Nguyen, L. T., Schmidt, H. A., Von Haeseler, A., & Minh, B. Q. (2015). IQ-TREE: A fast
469	and effective stochastic algorithm for estimating maximum-likelihood phylogenies.
470	<i>Molecular Biology and Evolution</i> , 32(1). https://doi.org/10.1093/molbev/msu300
471 472 473 474	 Nyiro, J. U., Munywoki, P., Kamau, E., Agoti, C., Gichuki, A., Etyang, T., Otieno, G., & James Nokes, D. (2018). Surveillance of respiratory viruses in the outpatient setting in rural coastal Kenya: Baseline epidemiological observations. <i>Wellcome Open Research</i>, <i>3</i>. https://doi.org/10.12688/wellcomeopenres.14662.1
475 476 477	O'Toole, Á., Aziz, A., & Maloney, D. (2024). Publication-ready single nucleotide polymorphism visualization with snipit. <i>Bioinformatics</i> , 40(8). https://doi.org/10.1093/BIOINFORMATICS/BTAE510
478	Parums, D. V. (2023). Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-
479	CoV-2 and its Rapid Global Spread. In <i>Medical Science Monitor</i> (Vol. 29).
480	https://doi.org/10.12659/MSM.939580
481	 Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J.,
482	Bolland, W. H., Porrot, F., Staropoli, I., Lemoine, F., Péré, H., Veyer, D., Puech, J.,
483	Rodary, J., Baele, G., Dellicour, S., Raymenants, J., Gorissen, S., Geenen, C.,
484	Schwartz, O. (2022). Considerable escape of SARS-CoV-2 Omicron to antibody
485	neutralization. <i>Nature</i> , 602(7898). https://doi.org/10.1038/s41586-021-04389-z
486	 Pybus, O. G., Suchard, M. A., Lemey, P., Bernardin, F. J., Rambaut, A., Crawford, F. W.,
487	Gray, R. R., Arinaminpathy, N., Stramer, S. L., Busch, M. P., & Delwart, E. L. (2012).
488	Unifying the spatial epidemiology and molecular evolution of emerging epidemics.
489	<i>Proceedings of the National Academy of Sciences of the United States of America</i> ,
490	109(37). https://doi.org/10.1073/pnas.1206598109
491	Rambaut, A., Drummond, A. J., Xie, D., Baele, G., & Suchard, M. A. (2018). Posterior
492	summarization in Bayesian phylogenetics using Tracer 1.7. <i>Systematic Biology</i> , 67(5).
493	https://doi.org/10.1093/sysbio/syy032
494	Rambaut, A., Lam, T. T., Carvalho, L. M., & Pybus, O. G. (2016). Exploring the temporal
495	structure of heterochronous sequences using TempEst (formerly Path-O-Gen). <i>Virus</i>
496	<i>Evolution</i> , 2(1). https://doi.org/10.1093/ve/vew007
497	Sagulenko, P., Puller, V., & Neher, R. A. (2018). TreeTime: Maximum-likelihood
498	phylodynamic analysis. <i>Virus Evolution</i> , 4(1). https://doi.org/10.1093/ve/vex042
499 500 501	 Suchard, M. A., Lemey, P., Baele, G., Ayres, D. L., Drummond, A. J., & Rambaut, A. (2018). Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. <i>Virus Evolution</i>, 4(1). https://doi.org/10.1093/ve/vey016

502 503 504 505 506	 Tamura, T., Ito, J., Uriu, K., Zahradnik, J., Kida, I., Anraku, Y., Nasser, H., Shofa, M., Oda, Y., Lytras, S., Nao, N., Itakura, Y., Deguchi, S., Suzuki, R., Wang, L., Begum, M. M., Kita, S., Yajima, H., Sasaki, J., Sato, K. (2023). Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. <i>Nature Communications</i>, <i>14</i>(1). https://doi.org/10.1038/s41467-023-38435-3
507 508 509 510 511 512	 Tegally, H., Moir, M., Everatt, J., Giovanetti, M., Scheepers, C., Wilkinson, E., Subramoney, K., Makatini, Z., Moyo, S., Amoako, D. G., Baxter, C., Althaus, C. L., Anyaneji, U. J., Kekana, D., Viana, R., Giandhari, J., Lessells, R. J., Maponga, T., Maruapula, D., de Oliveira, T. (2022). Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. <i>Nature Medicine</i>, <i>28</i>(9). https://doi.org/10.1038/s41591-022-01911-2
513 514 515 516 517	 Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., Mlisana, K., von Gottberg, A., Walaza, S., Allam, M., Ismail, A., Mohale, T., Glass, A. J., Engelbrecht, S., Van Zyl, G., de Oliveira, T. (2021). Detection of a SARS-CoV-2 variant of concern in South Africa. <i>Nature</i>, 592(7854). https://doi.org/10.1038/s41586-021-03402-9
518 519 520 521 522 523	 Viana, R., Moyo, S., Amoako, D. G., Tegally, H., Scheepers, C., Althaus, C. L., Anyaneji, U. J., Bester, P. A., Boni, M. F., Chand, M., Choga, W. T., Colquhoun, R., Davids, M., Deforche, K., Doolabh, D., du Plessis, L., Engelbrecht, S., Everatt, J., Giandhari, J., de Oliveira, T. (2022). Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. <i>Nature</i>, <i>603</i>(7902). https://doi.org/10.1038/s41586-022-04411-y
524 525 526 527	 Wang, Q., Iketani, S., Li, Z., Liu, L., Guo, Y., Huang, Y., Bowen, A. D., Liu, M., Wang, M., Yu, J., Valdez, R., Lauring, A. S., Sheng, Z., Wang, H. H., Gordon, A., Liu, L., & Ho, D. D. (2023). Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. <i>Cell</i>, <i>186</i>(2). https://doi.org/10.1016/j.cell.2022.12.018
528 529 530 531	 Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., & Tan, W. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. <i>New England Journal of Medicine</i>, 382(8). https://doi.org/10.1056/nejmoa2001017
532	